Home » News and Events » Events

Article: Now is the Time for Pharmaceutical Manufacturers to Invest
in Robust Systems for Calculating and Reporting Drug Prices

by McKenna Long & Aldridge and I-many, Inc.

Differences between a wide range of government programs have created a complex web of price reporting rules for pharmaceutical manufacturers, which, when coupled with the sheer volume of data involved in the calculations, are making automation of these calculations a business necessity. In fact, companies that fail to automate these processes, and at the same time address legal requirements, are at a much higher risk of generating and reporting prices that are inaccurate or erroneous—and of suffering significant penalties. Read more by downloading this article.

Please complete and submit the form (all fields are required).

First Name:
Last Name:
Title:
Company:
Phone:
Email:
State:**

**if outside of the U.S. or Canada,
select "N/A"
Country:
Website:
Industry:
Software Evaluation Timeframe:

Your question and comment:




 A complimentary article
co-authored by:


Donna Lee Yesner



Donna Lee Yesner is a Partner at McKenna Long & Aldridge LLP, a full-service law firm which provides business solutions in the areas of corporate law, government contracts, intellectual property and technology, complex litigation, public policy and regulatory affairs, international law, real estate, environmental, energy and finance.

[ back to top ]